Search: onr:"swepub:oai:DiVA.org:uu-341765" >
Preclinical evaluat...
Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy
-
- Mortensen, Anja (author)
- Uppsala universitet,Medicinsk strålningsvetenskap,Marika Nestor
-
- Spiegelberg, Diana, 1982- (author)
- Uppsala universitet,Öron-, näs- och halssjukdomar
-
- Haylock, Anna-Karin (author)
- Uppsala universitet,Öron-, näs- och halssjukdomar
-
show more...
-
- Lundqvist, Hans (author)
- Uppsala universitet,Medicinsk strålningsvetenskap
-
- Nestor, Marika, 1976- (author)
- Uppsala universitet,Medicinsk strålningsvetenskap
-
show less...
-
(creator_code:org_t)
- 2018-04-11
- 2018
- English.
-
In: International Journal of Oncology. - : Spandidos Publications. - 1019-6439 .- 1791-2423. ; 52:6, s. 1875-1885
- Related links:
-
https://doi.org/10.3...
-
show more...
-
https://uu.diva-port... (primary) (Raw object)
-
https://www.spandido...
-
https://urn.kb.se/re...
-
https://doi.org/10.3...
-
show less...
Abstract
Subject headings
Close
- CD44v6 is overexpressed in a variety of cancers, rendering it a promising target for radio-immunotherapy (RIT). In this study, we have characterized a novel engineered recombinant monoclonal anti-CD44v6 antibody, AbN44v6, and assessed its potential for use in RIT using either Lu-177 or I-131 as therapeutic radionuclides. In vitro affinity and specificity assays characterized the binding of the antibody labeled with Lu-177, I-125 or I-131. The therapeutic effects of Lu-177-AbN44v6 and I-131-AbN44v6 were investigated using two in vitro 3D tumor models with different CD44v6 expression. Finally, the normal tissue biodistribution and dosimetry for Lu-177-AbN44v6 and I-125-AbN44v6/I-131-AbN44v6 were assessed in vivo using a mouse model. All AbN44v6 radioconjugates demonstrated CD44v6-specific binding in vitro. In the in vitro 3D tumor models, dose-dependent therapeutic effects were observed with both Lu-177-AbN44v6 and I-131-AbN44v6, with a greater significant therapeutic effect observed on the cells with a higher CD44v6 expression. Biodistribution experiments demonstrated a greater uptake of Lu-177-AbN44v6 in the liver, spleen and bone, compared to I-125-AbN44v6, whereas I-125-AbN44v6 demonstrated a longer circulation time. In dosimetric calculations, the critical organs for Lu-177-AbN44v6 were the liver and spleen, whereas the kidneys and red marrow were considered the critical organs for I-131-AbN44v6. The effective dose was in the order of 0.1 mSv/MBq for both labels. In conclusion, AbN44v6 bound specifically and with high affinity to CD44v6. Furthermore, in vitro RIT demonstrated growth inhibition in a CD44v6-specific activity-dependent manner for both radioconjugates, demonstrating that both Lu-177-AbN44v6 and I-131-AbN44v6 may be promising RIT candidates. Furthermore, biodistribution and dosimetric analysis supported the applicability of both conjugates for RIT. The CD44v6-specific therapeutic effects observed with radiolabeled AbN44v6 in the 3D tumor models in vitro, combined with the beneficial dosimetry in vivo, render AbN44v6 a potential candidate for RIT.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Andra medicinska och farmaceutiska grundvetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Other Basic Medicine (hsv//eng)
Keyword
- radio-immunotherapy
- 3D tumor models
- dosimetry
- biodistribution
- 177Lu
- 131I
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database